3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol | 1607819-68-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol
• 英文别名: Ttc-352；3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol
• CAS: 1607819-68-0
• 化学式: C₂₀H₁₃FO₃S
• 分子量: 352.386
• InChiKey: UDBMVVLTKJMPCJ-UHFFFAOYSA-N

物化性质

• 沸点：
  559.1±50.0 °C(Predicted)
• 密度：
  1.409±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-bromo-3-(4-fluorophenyl)-6-methoxybenzo[b]thiophene 1-oxide 在 lithium aluminium tetrahydride 、 三溴化硼 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 5.75h， 生成 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS
  [FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES MÉDICAUX ASSOCIÉS AUX ŒSTROGÈNES

  摘要：

  本文揭示了治疗与雌激素相关的医学疾病的方法。治疗方法可能包括向需要此类治疗的对象施用含有至少一种化合物的组合物，该化合物符合以下公式（I）或其药用可接受盐的治疗有效量。

  公开号：

  WO2014066692A1

文献信息

• RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US20190224346A1

  公开（公告）日：2019-07-25

  Disclosed herein are 18 F-labeled compounds and compositions thereof. Also disclosed are methods of imaging estrogen receptor expressing tissues, or methods of identifying cancer lesions using these compounds.

  本文披露了18F标记的化合物及其组成物。还披露了使用这些化合物成像雌激素受体表达组织或识别癌症病变的方法。
• Compositions and methods for treating estrogen-related medical disorders
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US09895348B2

  公开（公告）日：2018-02-20

  Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本文揭示了治疗与雌激素相关的医疗疾病的方法。治疗方法可能包括向需要此类治疗的受试者施用含有至少一种式(I)化合物或其药学上可接受的盐的治疗有效量的组合物。
• COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS
  申请人：THATCHER Gregory R.

  公开号：US20150284357A1

  公开（公告）日：2015-10-08

  Disclosed is a compound of formula (I). or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions including the compound of formula (I) and methods of using the compound of formula (I).

  本发明揭示了一种式（I）的化合物或其药学上可接受的盐。还揭示了包括该式（I）化合物的药物组合物以及使用该式（I）化合物的方法。
• Diagnostic and therapeutic methods for the treatment of breast cancer
  申请人：GENENTECH, INC.

  公开号：US11081236B2

  公开（公告）日：2021-08-03

  Provided herein, inter alia, are predictive diagnostic, pharmacodynamic, and therapeutic methods for the treatment of breast cancer. In embodiments, the methods and compositions are based, at least in part, on the discovery that the estradiol (E2)-induced score or estrogen receptor (ER) pathway activity score determined from a sample (e.g., a tissue sample, e.g., a tumor tissue sample, e.g., a FFPE, a FF, an archival, a fresh, or a frozen tumor tissue sample) from an individual can be used in methods of determining whether the individual having breast cancer is likely to respond to a treatment including an endocrine therapy, selecting a therapy for an individual having breast cancer; treating an individual having breast cancer; and monitoring therapeutic efficacy of an endocrine therapy, as well as related kits.

  本文特别提供了治疗乳腺癌的预测性诊断、药效学和治疗方法。在实施方案中，这些方法和组合物至少部分基于以下发现：从样本（如组织样本，如肿瘤组织样本，如 FFPE、FF、存档样本、新鲜样本或ER）中确定的雌二醇（E2）诱导评分或雌激素受体（ER）通路活性评分、FFPE、FF、存档、新鲜或冷冻肿瘤组织样本）可用于确定乳腺癌患者是否可能对包括内分泌疗法在内的治疗产生反应、为乳腺癌患者选择疗法、治疗乳腺癌患者和监测内分泌疗法疗效的方法以及相关试剂盒。
• Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer
  作者：Rui Xiong、Hitisha K. Patel、Lauren M. Gutgesell、Jiong Zhao、Loruhama Delgado-Rivera、Thao N. D. Pham、Huiping Zhao、Kathryn Carlson、Teresa Martin、John A. Katzenellenbogen、Terry W. Moore、Debra A. Tonetti、Gregory R. J. Thatcher

  DOI：10.1021/acs.jmedchem.5b01276

  日期：2016.1.14

  Almost 70% of breast cancers are estrogen receptor alpha (ER alpha) positive. Tamoxifen, a selective estrogen receptor modulator (SERM), represents the standard of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics. Paradoxically, agonists at ER alpha such as estradiol (E-2) have demonstrated clinical efficacy in patients with heavily treated breast cancer, although side effects in gynecological tissues are unacceptable. A drug that selectively mimics the actions of E-2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative. We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ER alpha would provide such an agent. Novel benzothiophene derivatives with nanomolar potency in breast cancer cell cultures were designed. Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E-2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines. Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E-2, ShERPAs did not cause significant uterine growth.